Form 4: Royalty Pharma Executive Acquires Indirect Beneficial Ownership of Class E Ordinary Shares

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, reports an indirect acquisition of Class E ordinary shares through Royalty Pharma Holdings Ltd.

Summary

• Marshall Urist, an Executive Vice President at Royalty Pharma plc (RPRX), filed a Form 4 disclosing changes in his beneficial ownership.
• The report indicates an indirect acquisition of 1,356,528 Class E ordinary shares of Royalty Pharma Holdings Ltd (RPH).
• This acquisition is exempt under Rule 16b-3 and is related to the Membership Interests Purchase Agreement dated January 10, 2025.
• The Class E shares vest over a 9-year period and can be converted into Class B ordinary shares of RPH on a one-for-one basis.
• Class B shares can then be converted into Class A ordinary shares of Royalty Pharma plc, also on a one-for-one basis.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing indicating changes in ownership, not necessarily reflecting positive or negative performance.

Future Outlook

The vesting of Class E shares over a 9-year period suggests a long-term incentive structure for the executive.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The vesting schedule of the Class E shares could align the executive's interests with the long-term performance of the company, potentially benefiting shareholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Royalty Pharma, Marshall Urist, Class E Shares, RPRX, RPH